Skip to main content

Table 1 Characteristics of the enrolled patients overall and by length of treatment (group A: treatment lasting for 3 months and group B: treatment lasting for 6 months)

From: Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients

Variable Total n (%) Group A
n (%)
Group B
n (%)
p-value
Gender
 Male 46 (56.1) 35 (61.4) 11 (44)  
 Female 36 (43.9) 22 (38.6) 14 (56) 0.144
Age (years)
  ≤ 60 22 (26.8) 17 (29.8) 5 (20)  
 61–68 22 (26.8) 16 (28.1) 6 (24)  
 69–74 24 (29.3) 15 (26.3) 8 (32)  
  ≥ 75 14 (17.1) 9 (15.8) 6 (24) 0.666
Type of liver disease
 No cirrhosis or HCC 45 (54.9) 34 (59.6) 9 (36)  
 Cirrhosis 35 (42.7) 23 (40.4) 14 (56)  
 HCC with cirrhosis 2 (2.4) 0 (0) 2 (8) 0.025
Transient elastography
 None 7 (8.5)    
 F0 0 (0) 0 (0) 0 (0)  
 F1 2 (2.4) 2 (3.9) 0 (0)  
 F2 3 (3.8) 3 (5.9) 0 (0)  
 F3 33 (40.2) 29 (56.9) 3 (13)  
 F4 37 (45.1) 17 (33.3) 20 (87) < 0.01
HCV Genotype
 1a 2 (2.4) 1 (1.7) 1 (4)  
 1b 60 (73.3) 42 (73.7) 17 (68)  
 2 6 (7.3) 3 (5.3) 3 (12)  
 2a/2c 5 (6.1) 6 (10.5) 0 (0)  
 3 4 (4.8) 1 (1.7) 3 (12)  
 4 5 (6.1) 4 (7.1) 1 (4) 0.148
Co-infections
 None 81 (98.8) 56 (98.3) 25 (100)  
 HIV + 1 (1.2) 1 (1.7) 0 (0)  
 HBsAg +/HIV - 0 (0) 0 (0) (0) 0.505
BMI
 Normal 23 (28) 18 (31.6) 5 (20)  
 Overweight/Obese 59 (71.0) 39 (68.4) 20 (80) 0.283
Risk factors for CV diseasesa
 None 19 (23.2) 15 (26.3) 4 (16) 0.308
 Hypertension 51 (62.2) 34 (59.6) 17 (68) 0.473
 Diabetes mellitus 21 (25.6) 12 (21.1) 8 (32) 0.288
 Smoking habits 14 (17.1) 11 (19.3) 3 (12) 0.419
 Previous CV events 4 (4.8) 3 (5.3) 1 (4) 0.807
Comorbiditiesa
 None 19 (23.2) 15 (26.3) 4 (16) 0.308
 eGFR < 90 ml/min 43 (52.4) 32 (39) 11 (13.4) 0.350
 Osteoporosis 15 (18.3) 10 (17.6) 5 (20) 0.791
 Depression 14 (17.1) 11 (19.3) 3 (12) 0.419
  1. aEach patient may have more than one risk factors and comorbidities
  2. CV Cardiovascular, eGFR Estimated glomerular filtrate rate